Clinical trial
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With…
NCT00235937 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00235937 |
|---|---|
| Title | Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex |
| Official title | An Open, Phase II Trial Assessing the Objective Response Rate After Combination of Arimidex® 1mg Per os/Day and Zoladex® 3.6 mg Sub Cut/Monthly as 1st Treatment for Premenopausal Receptor Positive Advanced or Metastatic Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Anastrozole and goserelin |
| Enrollment | 45 |
| Start date | Dec 1, 2001 |
| Completion | Dec 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | Jan 21, 2011 |
| Countries | France |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: